Prothena to Participate in Jefferies Healthcare Conference
Prothena Corporation plc (NASDAQ:PRTA) announced that its senior management will participate in a fireside chat at the Jefferies Healthcare Conference on June 8, 2022, at 8:30 AM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Prothena Corporation plc (NASDAQ:PRTA) announced that its senior management will participate in a fireside chat at the Jefferies Healthcare Conference on June 8, 2022, at 8:30 AM ET. The event will be accessible via a live webcast on the company's investor relations website, with a replay available for 90 days afterward. Prothena focuses on developing therapeutics for neurodegenerative and rare peripheral amyloid diseases, leveraging its expertise in protein dysregulation. The company is advancing a robust pipeline targeting conditions like AL amyloidosis and Alzheimer's disease.
Details
News Market Reaction – PRTA
The recorded move for PRTA in the trading session of this news was +2.92%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DUBLIN, Ireland, June 02, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that members of its senior management team will participate in a fireside chat at the Jefferies Healthcare Conference on Wednesday June 8, 2022 at 8:30 AM ET.
A live webcast of the fireside chat can be accessed through the investor relations section of the Company's website at www.prothena.com. Following the live presentation, a replay of the webcast will be available on the Company's website for at least 90 days following the presentation date.
About Prothena
Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases. Fueled by its deep scientific expertise built over decades of research, Prothena is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Prothena’s pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a number of other neurodegenerative diseases. For more information, please visit the Company’s website at www.prothena.com and follow the Company on Twitter @ProthenaCorp.
Contacts:
Media
Eric Endicott, Senior Vice President, Corporate Affairs
650-448-3670, media@prothena.com
Investors
Jennifer Zibuda, Director, Investor Relations & Communications
650-837-8535, jennifer.zibuda@prothena.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.